Articles in Category: More News

ANALYSIS OF DRUGS IN CEREBRAL MICRODIALYSATES

News from Thursday, 14 April 2016.

pharm-analyt have recently joined forces with RenaSci (Nottingham) to offer a new service – measurement of drugs and neurotransmitters in the same microdialysate sample.

 

RenaSci employs dual-probe microdialysis to measure extracellular levels of neurotransmitter in different brain regions of freely-moving rats.

For example, they have recently measured the effects of d-amphetamine 0.5 mg/kg sc on dopamine levels in the nucleus accumbens and on acetylcholine levels in the prefrontal cortex. Microdialysate samples from this study were sent to pharm-analyt for analysis.

The results show an excellent correlation between d-amphetamine concentrations and dopamine levels in the nucleus accumbens and a weaker though still strong relationship between d-amphetamine concentrations and acetylcholine levels in the prefrontal cortex.

pharm-analyt is a fully-independent bioanalytical company based in Baden/Vienna. The company has been measuring small molecules and their metabolites in a variety of biological fluids and tissues for 30 years. For this purpose, they employ state-of-the-art instrumentation mass spectrometry technology. This enables them to quantify drug concentrations in minimal sample volumes with very high sensitivity.

Please click link below to see the data.

The ability to measure drug concentrations and neurotransmitter levels in the same microdialysate sample provides important information regarding the pharmacodynamic-pharmacokinetic properties of the drug.

For further information about this new service please contact us on This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it.

Certificate of Honor to CEO of pharm-analyt

News from Tuesday, 19 January 2016.

Certificate of Honor to CEO of pharm-analyt

We announce with pride that our CEO, Prof. Hermann Mascher received yet another award: The Certificate of Honor of the Austrian Society of Chemistry. 

The certificate recognizes the implementation of his profound chemical knowledge in scientifically sound and technically mature practice. Moreover, he is honored for meeting the international market´s high demands from a business point of view. Last, but not least, he is recognized for his commitment to the concerns of society as well as his employees.

 

 

 

 

Happy New Year!

News from Thursday, 07 January 2016.

Happy New Year!

Looking back, the last year was a rich year, full of blessings and exciting challenges!

In 2015, a little over half of our work derived from preclinical and clinical bioanalysis for Big Pharma organizations.

But many new projects were added, the majority of those highly innovative Biotech Projects. Often  this very early work has a highly experimental character.
Inhalable drugs have played a significant role again: Analysis at extremely sensitive levels (fg/mL plasma), yet with very low sample volumes (250µL plasma).

Oncology remains a huge topic: Here highly innovative delivery forms are being tried out, but also new drug concepts. Of course these topics require solid assays once in clinical studies.

In 2015 we have invested strongly in our equipment: All HPLC lines were upgraded, most significant was the purchase of another new mass spec line: QTRAP 6500.

We have enjoyed the intensive interactions, the high level discussions and the scouting for solutions of your challenges! May the new year be as exciting!

We are looking forward to yet another year of dialogue and good, long lasting collaborations!

Good success!

 

Hermann Mascher, CEO pharm-analyt

Pharm-Analyt Nominated for Innovation Award for Discovering Biomarkers

News from Thursday, 30 April 2015.

Baden, April 30th 2015

pharm-analyt was nominated for the innovation award “Kreativ in die Zukunft” ("Creatively Into the Future") in the category “Technical Innovation”.

The award is sponsered by the Austrian Economic Chamber.  The final prize will be awarded on June 10th in St. Pölten.

pharm-analyt discovered and validated specific substances (Small Molecules) in plasma that indicate particular genetic disorders with remarkably high specificity and sensitivity.

Three of these biomarkers were submitted and nominated for this innovation award: For Gaucher’s Disease, Niemann-Pick Type C and Metachromatic Leucodystrophy.
All three have orphan status with an incidence rate of 1:20,000, 1:150,000 and 1:50,000, respectively.